Aclaris Therapeutics Inc (NASDAQ:ACRS) major shareholder James E. Flynn sold 339,537 shares of the stock in a transaction that occurred on Friday, June 21st. The stock was sold at an average price of $4.62, for a total transaction of $1,568,660.94. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.
ACRS stock traded down $0.01 during midday trading on Thursday, hitting $2.10. The company’s stock had a trading volume of 280,876 shares, compared to its average volume of 607,114. The company has a debt-to-equity ratio of 0.16, a current ratio of 4.33 and a quick ratio of 4.30. The company has a market capitalization of $86.25 million, a price-to-earnings ratio of -0.52 and a beta of 0.77. Aclaris Therapeutics Inc has a 12 month low of $1.93 and a 12 month high of $20.75. The business has a 50 day moving average price of $3.69.
Aclaris Therapeutics (NASDAQ:ACRS) last posted its earnings results on Wednesday, May 8th. The biotechnology company reported ($0.91) EPS for the quarter, missing analysts’ consensus estimates of ($0.86) by ($0.05). The firm had revenue of $5.04 million for the quarter, compared to the consensus estimate of $5.13 million. Aclaris Therapeutics had a negative net margin of 999.53% and a negative return on equity of 78.05%. On average, analysts expect that Aclaris Therapeutics Inc will post -2.87 EPS for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of ACRS. Citigroup Inc. boosted its position in shares of Aclaris Therapeutics by 3,200.0% during the 4th quarter. Citigroup Inc. now owns 3,993 shares of the biotechnology company’s stock valued at $30,000 after acquiring an additional 3,872 shares during the last quarter. Great West Life Assurance Co. Can bought a new position in shares of Aclaris Therapeutics during the 4th quarter valued at approximately $43,000. BNP Paribas Arbitrage SA boosted its position in shares of Aclaris Therapeutics by 82,200.0% during the 1st quarter. BNP Paribas Arbitrage SA now owns 7,407 shares of the biotechnology company’s stock valued at $44,000 after acquiring an additional 7,398 shares during the last quarter. Legal & General Group Plc boosted its position in shares of Aclaris Therapeutics by 64.1% during the 4th quarter. Legal & General Group Plc now owns 6,495 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 2,536 shares during the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Aclaris Therapeutics during the 1st quarter valued at approximately $70,000. Hedge funds and other institutional investors own 91.79% of the company’s stock.
Aclaris Therapeutics Company Profile
Aclaris Therapeutics, Inc, a biopharmaceutical company, focuses on identifying, developing, and commercializing various therapies for dermatological and immuno-inflammatory diseases in the United States. It operates in two segments, Dermatology Therapeutics and Contract Research. The company offers ESKATA, a formulation of high-concentration hydrogen peroxide topical solution for raised seborrheic keratosis, a common non-malignant skin tumor; and RHOFADE, an oxymetazoline hydrochloride cream.
Featured Article: Price Target
Receive News & Ratings for Aclaris Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aclaris Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.